Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of “Moderate Buy” by Brokerages

Candel Therapeutics, Inc. (NASDAQ:CADL) has received a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $20.00.

Several equities research analysts have recently issued reports on CADL shares. Wall Street Zen raised Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Wednesday, October 8th. Brookline Capital Management raised Candel Therapeutics to a “strong-buy” rating in a research report on Wednesday, July 9th. Bank of America downgraded Candel Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $13.00 to $7.00 in a research report on Wednesday, September 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Candel Therapeutics in a research report on Monday, September 29th.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CADL. Tower Research Capital LLC TRC grew its position in Candel Therapeutics by 361.7% during the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after buying an additional 7,527 shares in the last quarter. Taylor Financial Group Inc. acquired a new stake in Candel Therapeutics during the first quarter worth about $56,000. Private Advisor Group LLC acquired a new stake in Candel Therapeutics during the first quarter worth about $58,000. Invesco Ltd. acquired a new stake in Candel Therapeutics during the first quarter worth about $59,000. Finally, AlphaQuest LLC acquired a new stake in Candel Therapeutics during the first quarter worth about $61,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Trading Down 1.7%

NASDAQ CADL opened at $5.33 on Friday. Candel Therapeutics has a 1-year low of $3.79 and a 1-year high of $14.60. The company has a current ratio of 7.04, a quick ratio of 7.04 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $292.62 million, a PE ratio of -7.72 and a beta of -0.94. The firm’s fifty day simple moving average is $5.55 and its 200-day simple moving average is $5.48.

Candel Therapeutics (NASDAQ:CADL) last posted its earnings results on Thursday, August 14th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. As a group, sell-side analysts anticipate that Candel Therapeutics will post -1.47 earnings per share for the current fiscal year.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.